1. United States
2. Calif.
3. Letter

The Food and Drug Administration's recent modifications to the risk evaluation and mitigation strategy for mifepristone aim to improve access to this medication used for reproductive healthcare. As the expert agency tasked with evaluating drug safety and efficacy, the FDA has determined that these changes are appropriate and will benefit those who need this service, especially those in underserved areas or facing personal difficulties. Restricting access to FDA-approved medications sets a concerning precedent of overriding scientific expertise with political ideology. Instead of undermining the FDA's role, we should trust their expert judgment and focus on expanding comprehensive healthcare services nationwide. Ensuring access to vital reproductive care empowers individuals to make personal decisions in consultation with their doctors, without undue government interference.